Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SAMUEL MOK and KWONG K WONG.
SAMUEL MOK
Connection Strength
3.693
KWONG K WONG
  1. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers. 2007; 23(5-6):367-76.
    View in: PubMed
    Score: 0.291
  2. Spatial Transcriptomics Depict Ligand-Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors. Cancer Res. 2023 05 02; 83(9):1503-1516.
    View in: PubMed
    Score: 0.226
  3. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques. 2001 Mar; 30(3):670-5.
    View in: PubMed
    Score: 0.194
  4. Pathogenesis and Clinical Management of Uterine Serous Carcinoma. Cancers (Basel). 2020 Mar 14; 12(3).
    View in: PubMed
    Score: 0.182
  5. ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. Cancers (Basel). 2018 Nov 22; 10(12).
    View in: PubMed
    Score: 0.166
  6. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 2018 02 01; 128(2):589-606.
    View in: PubMed
    Score: 0.156
  7. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget. 2017 Mar 07; 8(10):16951-16963.
    View in: PubMed
    Score: 0.147
  8. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016 Mar 29; 7:11150.
    View in: PubMed
    Score: 0.138
  9. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014 Oct 03; 5:5092.
    View in: PubMed
    Score: 0.125
  10. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol. 2013 Dec; 231(4):449-56.
    View in: PubMed
    Score: 0.118
  11. TGF-? modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 2013 Aug 15; 73(16):5016-28.
    View in: PubMed
    Score: 0.114
  12. Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol. 2013 Sep; 130(3):565-9.
    View in: PubMed
    Score: 0.114
  13. PAX2 Expression in Ovarian Cancer. Int J Mol Sci. 2013 Mar 15; 14(3):6090-105.
    View in: PubMed
    Score: 0.112
  14. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013 Feb 15; 19(4):809-20.
    View in: PubMed
    Score: 0.111
  15. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol. 2011 Oct; 123(1):13-8.
    View in: PubMed
    Score: 0.099
  16. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol. 2011 Jun; 35(6):904-12.
    View in: PubMed
    Score: 0.099
  17. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010 Oct; 177(4):1611-7.
    View in: PubMed
    Score: 0.094
  18. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009 Dec 08; 16(6):521-32.
    View in: PubMed
    Score: 0.089
  19. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol. 2009 Sep; 22(9):1243-50.
    View in: PubMed
    Score: 0.086
  20. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia. 2009 Jun; 11(6):529-41.
    View in: PubMed
    Score: 0.086
  21. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia. 2008 Sep; 10(9):964-72.
    View in: PubMed
    Score: 0.082
  22. Biomarker discovery in ovarian cancer. Womens Health (Lond). 2008 Jan; 4:27-40.
    View in: PubMed
    Score: 0.078
  23. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol. 2007 Jun 01; 25(16):2281-7.
    View in: PubMed
    Score: 0.075
  24. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res. 2007; 96:1-22.
    View in: PubMed
    Score: 0.073
  25. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia. 2006 Apr; 8(4):268-78.
    View in: PubMed
    Score: 0.069
  26. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res. 2005 Nov 01; 11(21):7651-7.
    View in: PubMed
    Score: 0.067
  27. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6880-8.
    View in: PubMed
    Score: 0.067
  28. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol. 2005 Jan; 96(1):77-83.
    View in: PubMed
    Score: 0.063
  29. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet. 2004 Dec; 155(2):97-107.
    View in: PubMed
    Score: 0.063
  30. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4782-91.
    View in: PubMed
    Score: 0.058
  31. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002 Apr 03; 287(13):1671-9.
    View in: PubMed
    Score: 0.052
  32. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst. 2001 Oct 03; 93(19):1458-64.
    View in: PubMed
    Score: 0.051
  33. Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. Cancers (Basel). 2020 Jan 02; 12(1).
    View in: PubMed
    Score: 0.045
  34. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene. 1998 May 07; 16(18):2381-7.
    View in: PubMed
    Score: 0.040
  35. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene. 1996 May 02; 12(9):1895-901.
    View in: PubMed
    Score: 0.035
  36. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol. 1994 Feb; 52(2):247-52.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.